Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 2359 Published: December 30, 2021 Report Code: GMDGDHC13209IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech.org

Bile Duct Cancer (Cholangiocarcinoma) pipeline market research report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects.

What are the key targets in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key targets in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and DNA. Programmed Cell Death 1 Ligand 1 has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by targets

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by targets

For more target insights, download a free report sample

What are the key MoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key MoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, DNA Synthesis Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 3 Inhibitor. Programmed Cell Death 1 Ligand 1 Inhibitor has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by MoA

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by MoA

For more MoA insights, download a free report sample

What are the key RoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key RoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Intravenous, Oral, Subcutaneous, Parenteral, Intravenous Drip, Intratumor, Intradermal, Intraperitoneal, Intravesical, Inhalational, and Intraarterial. Intravenous has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by RoA

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by RoA

For more RoA insights, download a free report sample

What are the key molecule types in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key molecule types in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Antisense RNAi Oligonucleotide, Oncolytic Virus, Biologic, and Oligonucleotide. Small Molecule has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by molecule type

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by molecule type

For more molecule type insights, download a free report sample

Which are the key companies in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key companies in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are AstraZeneca Plc, Eli Lilly and Co, Bayer AG, Jiangsu Hengrui Medicine Co Ltd, Alphamab Oncology, Hutchison MediPharma Ltd, Merck & Co Inc, BeiGene Ltd, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, and Advenchen Laboratories LLC. AstraZeneca Plc has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by companies

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Key targets Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and DNA
Key MoA Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, DNA Synthesis Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 3 Inhibitor
Key RoA Intravenous, Oral, Subcutaneous, Parenteral, Intravenous Drip, Intratumor, Intradermal, Intraperitoneal, Intravesical, Inhalational, and Intraarterial
Key molecule types Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Antisense RNAi Oligonucleotide, Oncolytic Virus, Biologic, and Oligonucleotide
Key companies AstraZeneca Plc, Eli Lilly and Co, Bayer AG, Jiangsu Hengrui Medicine Co Ltd, Alphamab Oncology, Hutchison MediPharma Ltd, Merck & Co Inc, BeiGene Ltd, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, and Advenchen Laboratories LLC

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
  • The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects
  • The report assesses Bile Duct Cancer (Cholangiocarcinoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Key Players

AbbVie Inc

Ability Pharmaceuticals SL

ABL Bio Inc

ABM Therapeutics Inc

ADC Therapeutics SA

Advenchen Laboratories LLC

Affimed GmbH

Akeso Inc

Alentis Therapeutics AG

Alphamab Oncology

Ambrx Biopharma Inc

Andes Biotechnologies

AngioGenex Inc

Apexigen Inc

Apollomics Inc

Arbele Ltd

Ascelia Pharma AB

Aslan Pharmaceuticals Ltd

AstraZeneca Plc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Biostar Technologies Ltd

Beijing Combio Pharmaceuticals Ltd

Beijing Immunochina Pharmaceuticals Co Ltd

Beijing Scitech-MQ Pharmaceuticals Ltd

Betta Pharmaceuticals Co Ltd

Biocad

BioMed Valley Discoveries Inc

BioNTech SE

Biotheus Inc

BJ Bioscience Inc

Blueprint Medicines Corp

Boehringer Ingelheim International GmbH

Bold Therapeutics Inc

BridgeBio Pharma Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

Cantargia AB

Celldex Therapeutics Inc

Cellestia Biotech AG

Celltrion Inc

Celon Pharma SA

Chineo Med Beijing Co Ltd

Chong Kun Dang Pharmaceutical Corp

Clovis Oncology Inc

Coherent Biopharma

Convalife

Corcept Therapeutics Inc

CSPC Pharmaceutical Group Ltd

CStone Pharmaceuticals Co Ltd

Curegenix Inc

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Delcath Systems Inc

Delta-Fly Pharma Inc

Eddingpharm Inc

Eisai Co Ltd

Eli Lilly and Co

Elucida Oncology Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Forma Therapeutics Inc

Fujifilm Holdings Corp

FUJIFILM Toyama Chemical Co Ltd

Genenta Science srl

Genexine Inc

GenFleet Therapeutics (Shanghai) Inc

GenoImmune Therapeutics Biotechnology Co Ltd

Genoscience Pharma

GI Innovation Co Ltd

GlaxoSmithKline Plc

GO Therapeutics Inc

Gracell Biotechnologies Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

H3 Biomedicine Inc

Hainan Kaibo Biotechnology Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Heidelberg Pharma AG

Huabo Biopharm (Shanghai) Co Ltd

Huahui Anjian (Beijing) Biotechnology Co Ltd

Hutchison MediPharma Ltd

ImCare Biotech LLC

Immix BioPharma Inc

ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

Immunitor Inc

Incyte Corp

Inmune Bio Inc

InnoCare Pharma Ltd

Innopharmax Inc

Innovent Biologics Inc

Inspirna Inc

Intensity Therapeutics Inc

Ipsen SA

J-Pharma Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kangen Pharmaceuticals Co Ltd

Kinnate Biopharma Inc

Komipharm International Co Ltd

KPC Pharmaceuticals Inc

Kyowa Kirin Co Ltd

LaNova Medicines Ltd

Leap Therapeutics Inc

Les Laboratoires Servier SAS

Ligand Pharmaceuticals Inc

LipoMedix Pharmaceutical Inc

Lokon Pharma AB

Luzitin SA

MacroGenics Inc

Medicenna Therapeutics Corp

MediciNova Inc

Medivir AB

Merck & Co Inc

Merck KGaA

Merus NV

Mina Therapeutics Ltd

Mirati Therapeutics Inc

Molecular Templates Inc

Mundipharma EDO GmbH

NanoCarrier Co Ltd

Netherlands Translational Research Center BV

Newish Technology Beijing Co Ltd

NGM Biopharmaceuticals Inc

Nkarta Inc

Northwest Biotherapeutics Inc

Novartis AG

NuCana Plc

Oasmia Pharmaceutical AB

Oncocross Co Ltd

Ono Pharmaceutical Co Ltd

Orgenesis Inc

PCI Biotech Holding ASA

Pfizer Inc

Pharma Mar SA

Pharmaxis Ltd

Phosplatin Therapeutics LLC

Pieris Pharmaceuticals Inc

Provecs Medical GmbH

Puma Biotechnology Inc

Puretech Health Plc

Quadriga BioSciences Inc

Rafael Pharmaceuticals Inc

RedHill Biopharma Ltd

Redx Pharma Plc

Relay Therapeutics Inc

RemeGen Co Ltd

Rhizen Pharmaceuticals SA

Samyang Biopharmaceuticals Corp

Sanofi

Seagen Inc

Seald AS

Senhwa Biosciences Inc

Shandong Boan Biotechnology Co Ltd

Shanghai Cell Therapy Group Co

Shanghai De Novo Pharmatech Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shanghai Haishi Biopharmaceutical Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Miracogen Inc

Shanghai Novamab Biopharmaceuticals Co Ltd

Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

Shenghe (China) Biopharmaceutical Co Ltd

Shouyao Holding Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

Sillajen Biotherapeutics

Silverback Therapeutics Inc

Sirnaomics Inc

SMT bio Co Ltd

Sorrento Therapeutics Inc

Sotio AS

SparkBioPharma Inc

Starpharma Holdings Ltd

Sun Pharma Advanced Research Company Ltd

SupremeCure Pharma Inc

Suzhou Hitebio Biotechnology Co Ltd

Suzhou Zelgen Biopharmaceutical Co Ltd

Symphogen A/S

SynCore Biotechnology Co Ltd

SyntheX Inc

Taiho Oncology Inc

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Tango Therapeutics Inc

TCR2 Therapeutics Inc

tella Inc

Tempest Therapeutics Inc

TerSera Therapeutics LLC

Therillia Development Co Inc

Toray Industries Inc

TOT Biopharm Co Ltd

Transcenta Holding Ltd

TransThera Sciences (Nanjing) Inc

Tyra Biosciences Inc

VasGene Therapeutics Inc

Virogin Biotech Ltd

Waterstone Hanxbio Pty Ltd

WellMarker Bio Co Ltd

Xencor Inc

Yantai Rongchang Pharmaceutical Co Ltd

Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd

Zhejiang Borui Biopharmaceutical Co Ltd

ZielBio Inc

Zymeworks Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bile Duct Cancer (Cholangiocarcinoma) – Overview

Bile Duct Cancer (Cholangiocarcinoma) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bile Duct Cancer (Cholangiocarcinoma) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bile Duct Cancer (Cholangiocarcinoma) – Companies Involved in Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma) – Drug Profiles

Bile Duct Cancer (Cholangiocarcinoma) – Dormant Projects

Bile Duct Cancer (Cholangiocarcinoma) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Bile Duct Cancer (Cholangiocarcinoma) – Dormant Projects, 2021

Bile Duct Cancer (Cholangiocarcinoma) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

The key targets in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and DNA.

The key MoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, DNA Synthesis Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 3 Inhibitor.

The key RoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Intravenous, Oral, Subcutaneous, Parenteral, Intravenous Drip, Intratumor, Intradermal, Intraperitoneal, Intravesical, Inhalational, and Intraarterial.

The key molecule types in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Antisense RNAi Oligonucleotide, Oncolytic Virus, Biologic, and Oligonucleotide.

The key companies in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are AstraZeneca Plc, Eli Lilly and Co, Bayer AG, Jiangsu Hengrui Medicine Co Ltd, Alphamab Oncology, Hutchison MediPharma Ltd, Merck & Co Inc, BeiGene Ltd, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, and Advenchen Laboratories LLC.

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.